Glioblastoma is the most common form of brain cancer in adults and one of the most deadly forms of any existing cancer. Besides being uncommonly aggressive while growing many tendrils that are nearly impossible to fully remove, glioblastoma is also difficult to treat because it is difficult to model.
One approach to discovering new potential treatments is to engineer lab-grown models of glioblastoma. Called organoids, these complex tissues mimic the structure and biology of tumors found in humans. These models, however, have a problem: Earth’s gravity interferes with their ability to form complex 3D structures and fully recreate real tumors.
With these limitations in mind, Meenal Datta, the Jane Schoelch DeFlorio Collegiate Professor of Aerospace and Mechanical Engineering, thought perhaps being weightless would help. To find out, she sent a few dozen glioblastoma organoids to the International Space Station (ISS) on SpaceX’s 30th commercial resupply mission.
According to her latest research results, her theory was correct. Published October 21 online in the journal Proceedings of the National Academy of Sciences (PNAS), research from Datta’s TIME Lab on their first in-space experiment shows that ISS-grown glioblastoma organoids containing both cancer and immune cells are more structurally sound and more closely replicate the biological behavior of glioblastoma tumors in patients than organoids grown on Earth for the same period of time.
More specifically, the researchers found that the space-grown tumors’ genes related to aggressive malignant behavior, inflammation, and tissue remodeling were more active. They also found that the levels of proteins associated with more aggressive glioblastoma biology were higher along with microenvironmental hallmarks that help tumors resist the body’s immune defenses.

The researchers also examined how these factors wax and wane spatially throughout an organoid’s mass. This further confirmed that the gene and protein expression patterns were not only more physiologically relevant than Earth-grown organoids, but also that they were in areas of the organoid (e.g., edge vs. core) that mirror their locations in human tumors.
“By growing glioblastoma organoids on the ISS, we demonstrated that microgravity fuels a model phenotype that recapitulates human tumors better and faster than we achieve on the ground,” said Datta. “This work helps lay the foundation for a new era of orbital oncology that moves cancer research from bedside to orbit and back again.”
With Space Tango, the implementation partner who provided hardware for the organoid growth, Datta’s lab has already sent over 1000 more patient-derived cancer and immune organoids this year to the ISS on SpaceX-34 and SpaceX-35. This round of experiments will lay the groundwork this approach to potentially help research and treat individual patients’ tumors.
Funding for this work was provided to various co-authors from the NSF, CASIS, AFOSR, Chan Zuckerberg Biohub, Azenta Oncology, the Walther Cancer Foundation, and the Notre Dame Edison Innovation Fellowship.
Datta is an associate professor in the Department of Aerospace and Mechanical Engineering, serves as a concurrent faculty member in the Department of Chemical and Biomolecular Engineering, and is a faculty adviser for Notre Dame’s graduate programs in bioengineering and materials science and engineering.
Datta is affiliated with Notre Dame’s Eck Institute for Global Health, the Berthiaume Institute for Precision Health, Harper Cancer Research Institute, NDnano, the Warren Center for Drug Discovery, the Lucy Family Institute for Data & Society, and the Boler-Parseghian Center for Rare Diseases.
